Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study

Chronic sympathetic nervous system (SNS) overactivity, characteristic of heart failure (HF) with reduced ejection fraction (HFrEF), is associated with poor prognosis and contributes to increased mortality risk. Sacubitril-valsartan is a recently approved, first-in-class, angiotensin receptor neprilysin inhibitor (ARNI) drug that markedly reduces the risks of death from cardiovascular causes and hospitalization for HF in patients with HFrEF, but the physiologic mechanisms underlying these benefits are not fully understood.

Source: Autonomic Neuroscience: Basic and Clinical - June 23, 2021 Category: Neuroscience Authors: Kanokwan Bunsawat, Stephen M. Ratchford, Jeremy K. Alpenglow, Josef Stehlik, Adam S. Smith, Russell S. Richardson, D. Walter Wray Source Type: research